As CIP2A has been reported to be involved in doxorubicin sensitivity [23], and that p-AKT represents a CIP2A downstream effector, we performedex vivoanalyses to investigate whether p-AKT could be involved in the appearance of resistance to doxorubicin in breast cancer. This evidence concerns the gene AKT1 and breast carcinoma.